Can common health conditions change the results of Alzheimer’s disease blood tests?
In a new study, our team at Karolinska Institutet and FBHI has examined blood samples from Karolinska University Hospital memory clinic patients, and found that some biomarkers for Alzheimer’s disease are more susceptible to common health conditions than others. Most biomarkers did remain stable, including the promising biomarker p-tau217, but others may be influenced by health factors like vascular problems and kidney function.
This means that the interpretation of test results must be adjusted for such factors, and that there is need for personalized approaches in biomarker testing, for more precise diagnostics. This knowledge is essential as the use of blood-based biomarkers is steadily moving closer to being part of clinical practice.
Read more:
Karolinska Institutet’s news item
Full article in Alzheimer’s & Dementia:
Enhancing diagnostic precision in Alzheimer’s disease: Impactof comorbidities on blood biomarkers for clinical integration
Authors:
Makrina Daniilidou, Ulf Öhlund-Wistbacka, Göran Hagman, Anna Rosenberg, Nicholas Ashton, Henrik Zetterberg, Kaj Blennow, Anna Matton, Miia Kivipelto.
Supported by, among others:
IHI-PROMINENT/BioArctic, IHI/AD-RIDDLE and Alzheimer’s Drug Discovery Foundation
